{"id":"pancreatic-enzyme-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain or cramping"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hyperuricemia (with high-dose use)"}]},"_chembl":{"chemblId":"CHEMBL4456859","moleculeType":"Unknown","molecularWeight":"4050.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The capsules contain a mixture of pancreatic enzymes that break down carbohydrates, fats, and proteins in the small intestine. In pancreatic insufficiency, the pancreas fails to produce adequate enzymes, leading to malabsorption; supplementation restores digestive capacity and nutrient absorption.","oneSentence":"Pancreatic enzyme capsules replace deficient pancreatic enzymes (amylase, lipase, protease) to restore normal digestion in patients with pancreatic insufficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:28.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic exocrine insufficiency"},{"name":"Chronic pancreatitis"},{"name":"Cystic fibrosis-related pancreatic insufficiency"},{"name":"Post-pancreatectomy malabsorption"}]},"trialDetails":[{"nctId":"NCT07441824","phase":"PHASE3","title":"Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-02","conditions":"Acute Necrotizing Pancreatitis, Pancreatic Exocrine Insufficiency","enrollment":140},{"nctId":"NCT04098237","phase":"PHASE2","title":"Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew Hendifar, MD","startDate":"2020-12-17","conditions":"Pancreatic Adenocarcinoma","enrollment":36},{"nctId":"NCT06058442","phase":"PHASE3","title":"The Pancreatic Enzymes After Gastrectomy Trial","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-01-24","conditions":"Gastrectomy","enrollment":188},{"nctId":"NCT07335523","phase":"PHASE2","title":"Management of Steatorrhea in Children and Young Adults With Alagille Syndrome After Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Digestive Care, Inc.","startDate":"2026-03","conditions":"Steatorrhea","enrollment":30},{"nctId":"NCT07314489","phase":"EARLY_PHASE1","title":"A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-01","conditions":"Chronic Pancreatitis Pancreatic Exocrine Insufficiency Blood Glucose","enrollment":80},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT06477159","phase":"PHASE4","title":"Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-02-01","conditions":"Exocrine Pancreatic Insufficiency","enrollment":60},{"nctId":"NCT07211568","phase":"PHASE3","title":"PERT in Acute Necrotizing Pancreatitis","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-10-01","conditions":"Acute Pancreatitis Necrotizing, Nutrition Assessment","enrollment":188},{"nctId":"NCT06826105","phase":"NA","title":"Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)","status":"RECRUITING","sponsor":"Philipp Schuetz","startDate":"2025-09-22","conditions":"Malnutrition","enrollment":20},{"nctId":"NCT07074379","phase":"NA","title":"Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-21","conditions":"Painless Chronic Pancreatitis","enrollment":126},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT06099119","phase":"PHASE4","title":"Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.","status":"RECRUITING","sponsor":"Hospital Clinico Universitario de Santiago","startDate":"2024-02-20","conditions":"Unresectable Pancreatic Cancer","enrollment":100},{"nctId":"NCT05266963","phase":"EARLY_PHASE1","title":"Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-09-02","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT06639516","phase":"NA","title":"Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2025-02-15","conditions":"Acute Pancreatitis","enrollment":60},{"nctId":"NCT05042284","phase":"NA","title":"Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis","status":"COMPLETED","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2021-09-01","conditions":"Chronic Pancreatitis, Pain","enrollment":107},{"nctId":"NCT05069597","phase":"PHASE4","title":"Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-10-14","conditions":"Cystic Fibrosis, Chronic Pancreatitis","enrollment":30},{"nctId":"NCT03551691","phase":"PHASE2","title":"Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-08-07","conditions":"Pancreatic Insufficiency, Cystic Fibrosis","enrollment":19},{"nctId":"NCT04949828","phase":"","title":"Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-09-16","conditions":"Chronic Pancreatitis","enrollment":63},{"nctId":"NCT06121245","phase":"NA","title":"The PRO-SOma COla (PROSOCO) Study","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2023-09-13","conditions":"Healthy","enrollment":11},{"nctId":"NCT06119880","phase":"PHASE4","title":"The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-11-01","conditions":"Pancreatic Exocrine Insufficiency, Pancreatic Enzyme Replacement Therapy, Pancreaticoduodenectomy","enrollment":100},{"nctId":"NCT03924947","phase":"PHASE4","title":"A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-10-23","conditions":"Cystic Fibrosis","enrollment":36},{"nctId":"NCT03859869","phase":"PHASE4","title":"A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2020-02-25","conditions":"Exocrine Pancreatic Insufficiency (EPI)","enrollment":1},{"nctId":"NCT04375878","phase":"PHASE2","title":"OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Entero Therapeutics","startDate":"2020-07-20","conditions":"Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)","enrollment":27},{"nctId":"NCT05261997","phase":"NA","title":"Endotherapy for Painless Chronic Pancreatitis","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-03","conditions":"Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain","enrollment":60},{"nctId":"NCT03450772","phase":"PHASE3","title":"Equivalence Study to Compare Two Strengths of Creon in China","status":"UNKNOWN","sponsor":"Abbott","startDate":"2017-08-31","conditions":"Pancreatic Insufficiency","enrollment":60},{"nctId":"NCT04315311","phase":"PHASE4","title":"Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2020-05-06","conditions":"Exocrine Pancreatic Insufficiency (EPI)","enrollment":""},{"nctId":"NCT05112328","phase":"NA","title":"The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2021-07-07","conditions":"Critically Ill, Enteral Feeding, Exocrine Pancreatic Insufficiency","enrollment":170},{"nctId":"NCT04966897","phase":"NA","title":"Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis","status":"COMPLETED","sponsor":"GlycosBio, Inc.","startDate":"2018-08-31","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":10},{"nctId":"NCT04570254","phase":"NA","title":"Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"Unidad Temporal COVID-19 en Centro Citibanamex","startDate":"2020-08-19","conditions":"Pneumonia, Viral, Covid19, ARDS","enrollment":110},{"nctId":"NCT02985801","phase":"PHASE1, PHASE2","title":"PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Massimo Raimondo, M.D.","startDate":"2016-12","conditions":"Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality","enrollment":16},{"nctId":"NCT02097394","phase":"PHASE4","title":"The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2013-06","conditions":"Combizym, Bifidobacteri, Colon Polyps","enrollment":200},{"nctId":"NCT01159119","phase":"PHASE1","title":"A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2010-08-02","conditions":"Chronic Pancreatitis","enrollment":15},{"nctId":"NCT01865695","phase":"PHASE4","title":"Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase","status":"TERMINATED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2013-05","conditions":"Patients With Coeliac Disease and Chronic Diarrhoea (>3 Loose/ Liquid Motions a Day for More Than 4 Weeks), Patients With Pancreatic Exocrine Insufficiency","enrollment":2},{"nctId":"NCT02849704","phase":"PHASE2","title":"Fat Malabsorption in Chronic Pancreatitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2016-10-13","conditions":"Chronic Pancreatitis","enrollment":48},{"nctId":"NCT01641341","phase":"PHASE4","title":"Irritable Bowel Syndrome Evaluation and Treatment in Primary Care","status":"COMPLETED","sponsor":"American Academy of Family Physicians","startDate":"2010-11","conditions":"Irritable Bowel Syndrome","enrollment":61},{"nctId":"NCT02127021","phase":"PHASE4","title":"The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-04","conditions":"Pancreaticoduodenectomy","enrollment":304},{"nctId":"NCT01859390","phase":"PHASE2","title":"Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06","conditions":"Cystic Fibrosis","enrollment":73},{"nctId":"NCT01131507","phase":"PHASE4","title":"PR-018: An Open-Label, Safety Extension of Study PR-011","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-07","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":15},{"nctId":"NCT00981214","phase":"PHASE3","title":"Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-05","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":19},{"nctId":"NCT00880100","phase":"PHASE3","title":"Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-04","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":49},{"nctId":"NCT00513682","phase":"PHASE3","title":"Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-07","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":9},{"nctId":"NCT00408317","phase":"PHASE3","title":"Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-11","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":36},{"nctId":"NCT00297167","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-05","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":34},{"nctId":"NCT02137382","phase":"PHASE3","title":"A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","sponsor":"Abbott","startDate":"2014-01","conditions":"Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","enrollment":41},{"nctId":"NCT01587534","phase":"PHASE2","title":"Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2011-10","conditions":"Pancreatic Cancer","enrollment":67},{"nctId":"NCT01430234","phase":"PHASE4","title":"Enzyme Suppletion in Exocrine Pancreatic Dysfunction","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2011-10","conditions":"Chronic Pancreatitis, Exocrine Pancreatic Insufficiency","enrollment":10},{"nctId":"NCT00095732","phase":"PHASE2","title":"Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency","status":"COMPLETED","sponsor":"Anthera Pharmaceuticals","startDate":"2004-06","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":129},{"nctId":"NCT02009410","phase":"PHASE4","title":"A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2","status":"WITHDRAWN","sponsor":"Abbott","startDate":"2013-11","conditions":"Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2","enrollment":""},{"nctId":"NCT00662675","phase":"PHASE3","title":"A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-08","conditions":"Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes","enrollment":40},{"nctId":"NCT01100606","phase":"PHASE4","title":"A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-06","conditions":"Cystic Fibrosis, Exocrine Pancreatic Insufficiency","enrollment":15},{"nctId":"NCT01641393","phase":"PHASE3","title":"Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-06","conditions":"Exocrine Pancreatic Insufficiency: Cystic Fibrosis","enrollment":96},{"nctId":"NCT00788593","phase":"PHASE3","title":"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-01","conditions":"Chronic Pancreatitis, Exocrine Pancreatic Insufficiency","enrollment":82},{"nctId":"NCT00744250","phase":"PHASE4","title":"Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control","status":"TERMINATED","sponsor":"Digestive Care, Inc.","startDate":"2008-08","conditions":"Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis","enrollment":3},{"nctId":"NCT00749099","phase":"NA","title":"Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)","status":"TERMINATED","sponsor":"Digestive Care, Inc.","startDate":"2007-04","conditions":"Exocrine Pancreatic Insufficiency","enrollment":11},{"nctId":"NCT01142128","phase":"PHASE1","title":"Viokase 16, Viokase16 Plus Nexium and Nexium Alone","status":"TERMINATED","sponsor":"University of Florida","startDate":"2009-02","conditions":"Chronic Pancreatitis","enrollment":12},{"nctId":"NCT00432861","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis","status":"COMPLETED","sponsor":"Digestive Care, Inc.","startDate":"2007-01","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":29},{"nctId":"NCT00535756","phase":"PHASE4","title":"Creon After Pancreatic Surgery","status":"COMPLETED","sponsor":"Abbott Products","startDate":"2008-04","conditions":"Pancreatic Insufficiency","enrollment":58},{"nctId":"NCT00705978","phase":"PHASE3","title":"Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis","status":"COMPLETED","sponsor":"Abbott Products","startDate":"2008-06","conditions":"Pancreatic Insufficiency","enrollment":62},{"nctId":"NCT00676702","phase":"PHASE1","title":"A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-07","conditions":"Exocrine Pancreatic Insufficiency, Pancreatitis, Chronic, Steatorrhea","enrollment":13},{"nctId":"NCT00663975","phase":"NA","title":"Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients","status":"WITHDRAWN","sponsor":"Digestive Care, Inc.","startDate":"2009-02","conditions":"Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis","enrollment":24},{"nctId":"NCT00160186","phase":"PHASE4","title":"Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2003-12","conditions":"Gastrectomy","enrollment":40},{"nctId":"NCT00006063","phase":"NA","title":"Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-07","conditions":"Cystic Fibrosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pancreatic enzyme capsules","genericName":"Pancreatic enzyme capsules","companyName":"Asian Institute of Gastroenterology, India","companyId":"asian-institute-of-gastroenterology-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pancreatic enzyme capsules replace deficient pancreatic enzymes (amylase, lipase, protease) to restore normal digestion in patients with pancreatic insufficiency. Used for Pancreatic exocrine insufficiency, Chronic pancreatitis, Cystic fibrosis-related pancreatic insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}